检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Efficacy and Safety of Oral Ritlecitinib for the Treatment of Active Nonsegmental Vitiligo: A Randomized Phase 2b Clinical Trial.

Khaled Ezzedine,Elena Peeva,Yuji Yamaguchi,Lori Ann Cox,Anindita Banerjee,George Han,Iltefat Hamzavi,Anand K Ganesan,Mauro Picardo,Diamant Thaçi,John E Harris,Jung Min Bae,Katsuhiko Tsukamoto,Rodney Sinclair,Amit G Pandya, Abigail Sloan, Dahong Yu,Kavita Gandhi,Michael S Vincent,Brett King

Journal of the American Academy of Dermatology（2022）

引用 12|浏览33
暂无评分
摘要
Oral ritlecitinib was effective and well-tolerated over 48 weeks in patients with active NSV.
更多
查看译文
关键词
JAK inhibitor,JAK/STAT signaling,TEC inhibitor,VASI,Vitiligo,randomized clinical trial,ritlecitinib,skin depigmentation
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要